Semax
Pending PCACAlso known as: Heptapeptide, MEHFPGP
Nootropic & NeuroprotectiveLast reviewed: April 28, 2026
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
Mechanism of Action
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
Common Uses
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
Known Risks
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
Get notified when the PCAC decides on Semax
Scheduled review: July 24, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Intranasal spray
Typical Dose
200–600 mcg
Frequency
1–2x daily
Cycle Length
2–4 weeks on, 1–2 weeks off
Most common delivery method. Each spray typically delivers ~100 mcg. Often stacked with Selank for anxiolytic balance. Use in the morning for focus/energy effects.
Subcutaneous injection
Typical Dose
100–300 mcg
Frequency
Once daily
Cycle Length
2–4 weeks
Higher bioavailability than intranasal. Less common due to injection burden.
Related Compounds
Research References
Related Articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
regulatory · 5 min read
What Is Semax? Uses, Risks, and FDA Status
guide · 3 min read
How to Submit a Public Comment to the FDA Before July 9 (Step-by-Step)
regulatory · 9 min read
What Category 2 Removal Actually Means (And What It Doesn't)
regulatory · 5 min read
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.